PTC/SB/08a (08-03 )
Approved for use through 97/31/2006, ONE 0851-0231
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

	Application Number			
	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor STEI		EINER et al.	
( Not for submission under 37 CFR 1.99)	Art Unit		N/A	
	Examiner Name N/A			
	Attorney Docket Numb	er	72208	

U.S.PATENTS								Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue [	Date	Name of Patentee or Applicant		Relev	Pages,Columns,Lines w Relevant Passages or R Figures Appear		
	1	2438548		1948-0	3-30	Ehmann					
	2	1672867		1928-0	6-12	Bazoley et al.					
	3	1385554		1921-0	7-26	Jones					
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	hber   Kind   Publication   Name of Patentee or Applicant			Relev		Lines where ges or Relev			
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d buttor	$\overline{}$		
	FOREIGN PATENT DOCUMENTS Remove										
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date Name of Patentee of Applicant of cited Document		e or	where Rel	or Relevant	Ts
	1	WO01/90598A1	DE			2001-11-29	Steiner et al.		1-4,6,8,2, 1	19-21	

#### Application Number Filing Date INFORMATION DISCLOSURE First Named Inventor STEINER et al STATEMENT BY APPLICANT Art I Init N/A ( Not for submission under 37 CFR 1.99) Examiner Name N/A Attorney Docket Number 72208

	2	FR861864	FR		1939-11-24	Pollard et al.	1, 3, 8, 19-21		
	3	EP0680395B1	EP		1995-08-11	Platiner	1, 20		
	4	FR1357117	FR		1963-02-22	Bannet-Thinan			
	5	DE85444	DE		1920-06-16	Taylor			
	6	DE154329	DE		1903-12-24	Menck & Hambrock			
	7	DE153785	DE		1902-09-07	Menck & Hambrock			
	8	DE133348	DE		1901-11-14	Diton Herbert Abney			
	9	FR1249601	FR		1960-02-25	Maulvault			
If you wish	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n Add	_	
	NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner	Cite					the article (when approp date, pages(s), volume-is		Тs	

publisher, city and/or country where published.

If you wish to add additional non-patent literature document citation information please click the Add button Add

EFS Web 1.0

	Application Number			
	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor STEI		INER et al.	
( Not for submission under 37 CFR 1.99)	Art Unit		N/A	
(Not lot sasimission ander or or it isoy	Examiner Name N/A			
	Attorney Docket Number		72208	

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
EVAMINED: Initial if reference considered, whether or not citation is in conformance with MDED 800. Draw line through a						

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kinc Code of USPTO Petert Documents at sweet USPTO\_CODY or MPEP 96104. I Enter office that issued the document, by the shoulders of WIPO Standard ST3.) "The planese peter for comment, he ancidated on the year of the register man precise the sent antimeter of the patient format of the Captact marker precise the sent antimeter of the patient format of the Captact marker of the patient format precise the sent ancient of the patient format of the Captact marker of the Captact m

#### 

## CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1:97(e)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 177(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

7 None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/john james mcglew/	Date (YYYY-MM-DD)	
Name/Print	John James McGlew	Registration Number	31903

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.